FXRα down-regulates LXRα signaling at the CETP promoter via a common element

Molecules and Cells

Volumn 26, Issue 4, 2008, Pages 409-414

  Park, Sung Soo ^a   Choi, Hojung ^a   Kim, Seung Jin ^a   Chae, Kwon Seok ^b   Kim, Eungseok ^a  

^a Chonnam National University   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

CETP; DR4RE; FXR; LXR

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; CHENODEOXYCHOLIC ACID; CHOLESTEROL ESTER TRANSFER PROTEIN; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR ALPHA; LIGAND; LIVER X RECEPTOR ALPHA; LUCIFERASE; MESSENGER RNA; UNCLASSIFIED DRUG; CELL RECEPTOR; CETP PROTEIN, HUMAN; DNA BINDING PROTEIN; FARNESOID X-ACTIVATED RECEPTOR; LIVER X RECEPTOR; RETINOID X RECEPTOR ALPHA; TRANSCRIPTION FACTOR;

ARTICLE; BASAL CELL; BINDING AFFINITY; CELL STRAIN HEPG2; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; BINDING COMPETITION; CELL LINE; DNA RESPONSIVE ELEMENT; DOWN REGULATION; DRUG EFFECT; GENETICS; METABOLISM; PROTEIN BINDING; PROTEIN MULTIMERIZATION;

BINDING, COMPETITIVE; CELL LINE; CHENODEOXYCHOLIC ACID; CHOLESTEROL ESTER TRANSFER PROTEINS; DNA-BINDING PROTEINS; DOWN-REGULATION; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RESPONSE ELEMENTS; RETINOID X RECEPTOR ALPHA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 58049192518     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Agerholm-Larsen, B., Nordestgaard, B.G., Steffensen, R., Jensen, G., and Tybjaerg-Hansen, A. (2000). Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 101, 1907-1912.
2. Barzilai, N., Atzmon, G., Schechter, C., Schaefer, E.J., Cupples, A.L., Lipton, R., Cheng, S., and Shuldiner, A.R. (2003). Unique lipoprotein phenotype and genotype associated with exceptional longevity. Jama 290, 2030-2040.
3. Blankenberg, S., Rupprecht, H.J., Bickel, C., Jiang, X.C., Poirier, O., Lackner, K.J., Meyer, J., Cambien, F., and Tiret, L. (2003). Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. J. Am. Coll. Cardiol. 41, 1983-1989.
4. Claudel, T., Sturm, E., Duez, H., Torra, I.P., Sirvent, A., Kosykh, V., Fruchart, J.C., Dallongeville, J., Hum, D.W., Kuipers, F., et al. (2002). Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J. Clin. Invest. 109, 961-971.
5. Claudel, T., Inoue, Y., Barbier, O., Duran-Sandoval, D., Kosykh, V., Fruchart, J., Fruchart, J.C., Gonzalez, F.J., and Staels, B. (2003). Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 125, 544-555.
6. de Grooth, G.J., Zerba, K.E., Huang, S.P., Tsuchihashi, Z., Kirchgessner, T., Belder, R., Vishnupad, P., Hu, B., Klerkx, A.H., Zwinderman, A.H., et al. (2004). The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular out come and interaction with cholesterol-lowering therapy. J. Am. Coll. Cardiol. 43, 854-857.
7. del Castillo-Olivares, A., and Gil, G. (2000). Role of FXR and FTF in bile acid-mediated suppression of cholesterol 7alpha-hydro-xylase transcription. Nucleic Acids Res. 28, 3587-3593.
8. Forman, B.M., Goode, E., Chen, J., Oro, A.E., Bradley, D.J., Perlmann, T., Noonan, D.J., Burka, L.T., McMorris, T., Lamph, W.W., et al. (1995). Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81, 687-693.
9. Giguere, V. (1999). Orphan nuclear receptors: from gene to function. Endocr. Rev. 20, 689-725.
10. Goodwin, B., Jones, S.A., Price, R.R., Watson, M.A., McKee, D.D., Moore, L.B., Galardi, C., Wilson, J.G., Lewis, M.C., Roth, M.E., et al. (2000). A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6, 517-526.
11. Hanniman, E.A., Lambert, G., McCarthy, T.C., and Sinal, C.J. (2005). Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46, 2595-2604.
12. Kim, E., Xie, S., Yeh, S.D., Lee, Y.F., Collins, L.L., Hu, Y.C., Shyr, C.R., Mu, X.M., Liu, N.C., Chen, Y.T., et al. (2003). Disruption of TR4 orphan nuclear receptor reduces the expression of liver apolipoprotein E/ C-I/C-II gene cluster. J. Biol. Chem. 278, 46919-46926.
13. Kim, E., Yang, Z., Liu, N.C., and Chang, C. (2005). Induction of apolipoprotein E expression by TR4 orphan nuclear receptor via 5′ proximal promoter region. Biochem. Biophys. Res. Commun. 328, 85-90.
14. Laffitte, B.A., Kast, H.R., Nguyen, C.M., Zavacki, A.M., Moore, D.D., and Edwards, P.A. (2000). Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J. Biol. Chem. 275, 10638-10647.
15. Lambert, G., Amar, M.J., Guo, G., Brewer, H.B. Jr., Gonzalez, F.J., and Sinal, C.J. (2003). The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278, 2563-2570.
16. Lu, T.T., Makishima, M., Repa, J.J., Schoonjans, K., Kerr, T.A., Auwerx, J., and Mangelsdorf, D.J. (2000). Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6, 507-515.
17. Luo, Y., and Tall, A.R. (2000). Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J. Clin. Invest. 105, 513-520.
18. Luo, Y., Liang, C.P., and Tall, A.R. (2001). The orphan nuclear receptor LRH-1 potentiates the sterol-mediated induction of the human CETP gene by liver X receptor. J. Biol. Chem. 276, 24767-24773.
19. Makishima, M., Okamoto, A.Y., Repa, J.J., Tu, H., Learned, R.M., Luk, A., Hull, M.V., Lustig, K.D., Mangelsdorf, D.J., and Shan, B. (1999). Identification of a nuclear receptor for bile acids. Science 284, 1362-1365.
20. Parks, D.J., Blanchard, S.G., Bledsoe, R.K., Chandra, G., Consler, T.G., Kliewer, S.A., Stimmel, J.B., Willson, T.M., Zavacki, A.M., Moore, D.D., et al. (1999). Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365-1368.
21. Sinal, C.J., Tohkin, M., Miyata, M., Ward, J.M., Lambert, G., and Gonzalez, F.J. (2000). Targeted disruption of the nuclear receptor FXR/ BAR impairs bile acid and lipid homeostasis. Cell 102, 731-744.
22. Sperker, B., Mark, M., and Budzinski, R.M. (1993). The expression of human plasma cholesteryl-ester-transfer protein in HepG2 cells is induced by sodium butyrate. Quantification of low mRNA levels by polymerase chain reaction. Eur. J. Biochem. 218, 945-950.
23. Watanabe, M., Houten, S.M., Wang, L., Moschetta, A., Mangelsdorf, D.J., Heyman, R.A., Moore, D.D., and Auwerx, J. (2004). Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113, 1408-1418.
24. Willy, P.J., Umesono, K., Ong, E.S., Evans, R.M., Heyman, R.A., and Mangelsdorf, D.J. (1995). LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9, 1033-1045.
25. Zhang, Y., Wang, X., Vales, C., Lee, F.Y., Lee, H., Lusis, A.J., and Edwards, P.A. (2006). FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler. Thromb. Vasc. Biol. 26, 2316-2321.